Ma J - Search Results

1

Current sample handling methods for measurement of platinum-DNA adducts in leucocytes in man lead to discrepant results in DNA adduct levels and DNA repair.

Ma J, Verweij J, Planting AS, de Boer-Dennert M, van Ingen HE, van der Burg ME, Stoter G, Schellens JH. Ma J, et al. Br J Cancer. 1995 Mar;71(3):512-7. doi: 10.1038/bjc.1995.102. Br J Cancer. 1995. PMID: 7880732 Free PMC article.

2

Pharmacokinetic-dynamic relationship of cisplatin in vitro: simulation of an i.v. bolus and 3 h and 20 h infusion.

Ma J, Verweij J, Kolker HJ, van Ingen HE, Stoter G, Schellens JH. Ma J, et al. Br J Cancer. 1994 May;69(5):858-62. doi: 10.1038/bjc.1994.166. Br J Cancer. 1994. PMID: 8180014 Free PMC article.

3

Docetaxel and paclitaxel inhibit DNA-adduct formation and intracellular accumulation of cisplatin in human leukocytes.

Ma J, Verweij J, Planting AS, Kolker HJ, Loos WJ, de Boer-Dennert M, van der Burg ME, Stoter G, Schellens JH. Ma J, et al. Cancer Chemother Pharmacol. 1996;37(4):382-4. doi: 10.1007/s002800050401. Cancer Chemother Pharmacol. 1996. PMID: 8548886 Free article.

4

Relationship between the exposure to cisplatin, DNA-adduct formation in leucocytes and tumour response in patients with solid tumours.

Schellens JH, Ma J, Planting AS, van der Burg ME, van Meerten E, de Boer-Dennert M, Schmitz PI, Stoter G, Verweij J. Schellens JH, et al. Among authors: ma j. Br J Cancer. 1996 Jun;73(12):1569-75. doi: 10.1038/bjc.1996.296. Br J Cancer. 1996. PMID: 8664132 Free PMC article.

5

Comparison of ethanol plasma-protein precipitation with plasma ultrafiltration and trichloroacetic acid protein precipitation for the measurement of unbound platinum concentrations.

Ma J, Stoter G, Verweij J, Schellens JH. Ma J, et al. Cancer Chemother Pharmacol. 1996;38(4):391-4. doi: 10.1007/s002800050501. Cancer Chemother Pharmacol. 1996. PMID: 8674165 Free article.

6

Abrogated energy-dependent uptake of cisplatin in a cisplatin-resistant subline of the human ovarian cancer cell line IGROV-1.

Ma J, Maliepaard M, Kolker HJ, Verweij J, Schellens JH. Ma J, et al. Cancer Chemother Pharmacol. 1998;41(3):186-92. doi: 10.1007/s002800050727. Cancer Chemother Pharmacol. 1998. PMID: 9443634

7

Synergistic cytotoxicity of cisplatin and topotecan or SN-38 in a panel of eight solid-tumor cell lines in vitro.

Ma J, Maliepaard M, Nooter K, Boersma AW, Verweij J, Stoter G, Schellens JH. Ma J, et al. Cancer Chemother Pharmacol. 1998;41(4):307-16. doi: 10.1007/s002800050744. Cancer Chemother Pharmacol. 1998. PMID: 9488600

8

Reduced cellular accumulation of topotecan: a novel mechanism of resistance in a human ovarian cancer cell line.

Ma J, Maliepaard M, Nooter K, Loos WJ, Kolker HJ, Verweij J, Stoter G, Schellens JH. Ma J, et al. Br J Cancer. 1998 May;77(10):1645-52. doi: 10.1038/bjc.1998.270. Br J Cancer. 1998. PMID: 9635842 Free PMC article.

9

Phase I and pharmacologic study of the arotinoid Ro 40-8757 in combination with cisplatin and etoposide in patients with non-small cell lung cancer.

van Zuylen L, Schellens JH, Goey SH, Pronk LC, de Boer-Dennert MM, Loos WJ, Ma J, Stoter G, Verweij J. van Zuylen L, et al. Among authors: ma j. Anticancer Drugs. 1999 Apr;10(4):361-8. doi: 10.1097/00001813-199904000-00003. Anticancer Drugs. 1999. PMID: 10378670 Clinical Trial.

10

Adaptive intrapatient dose escalation of cisplatin in patients with advanced head and neck cancer.

Schellens JH, Planting AS, Ma J, Maliepaard M, de Vos A, de Boer Dennert M, Verweij J. Schellens JH, et al. Among authors: ma j. Anticancer Drugs. 2001 Sep;12(8):667-75. doi: 10.1097/00001813-200109000-00004. Anticancer Drugs. 2001. PMID: 11604553 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

38,276 results

Search Page

Filters